A two-way ANOVA to assess drug (NGD 98-2 and NGD 9002) and dose (0, 3, 10 and 30 mg/kg) interactions showed a significant main effect of drug (p<0.01) as well as dose (p<0.01) on icv CRF-induced FPO response and no significant interaction between drug type and dose (P = 0.396). The gene discussed is CRH; the disease is otopalatodigital syndrome type 2.